NasdaqGM - Nasdaq Real Time Price USD

XOMA Corporation (XOMA)

24.59

+0.34

(+1.40%)

At close: April 18 at 4:00 PM EDT

24.59

0.00

(0.00%)

After hours: April 18 at 4:02 PM EDT

XOMA Corporation Announces Closing of Tender Offer

Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value RightEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KN

GlobeNewswire 15 days ago

KNTE

XOMA
+1.40%
XOMAO
XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series

GlobeNewswire 28 days ago

XOMA
+1.40%
XOMAO

XOMAP
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolioEMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (“Kinnate”; Nasdaq: KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share

GlobeNewswire 30 days ago

XOMA
+1.40%
XOMAO

XOMAP
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023

Key Financial Highlights and Upcoming Events Set to Influence Future Growth

GuruFocus.com last month

XOMA
+1.40%
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing royalty base and the achievement of certain development milestones during 2023 Added third commercial asset to XOMA’s portfolio with the acquisition of economic interests in DSUVIA® (sufentanil sublingual tablet) in January 2024 Closed 2023 with two partners’ New Drug Applications (ND

GlobeNewswire last month

XOMA
+1.40%
XOMAO

XOMAP
XOMA to Present at Upcoming Investor Conferences in March

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences: The 44th Annual TD Cowen Health Care Conference taking place March 4-6, 2024, in Boston, MA. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat on Wednesday, March 6, 2024, at 10:30 AM ET. The presentati

GlobeNewswire last month

XOMA
+1.40%
XOMAO

XOMAP
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolioEMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0.2527 per share (together with th

GlobeNewswire 2 months ago

XOMA
+1.40%
XOMAO

XOMAP
With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors

Key Insights Significantly high institutional ownership implies XOMA's stock price is sensitive to their trading...

Simply Wall St. 2 months ago

XOMA
+1.40%
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of Defense purchases XOMA is entitled to no less than 50% of the potential $116.5 million in milestone payments EMERYVILLE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has acquired an economic interest in DSUVIA® (sufentanil sublingual tablet)

GlobeNewswire 2 months ago

XOMA
+1.40%
XOMAO

XOMAP
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA) acceptance of Zevra Therapeutics’ New Drug Application (NDA) for arimoclomol, an orally-delivered, first-in-class therapy for Niemann-Pick disease type C (NPC), XOMA will make a $1 million milestone

GlobeNewswire 3 months ago

XOMA
+1.40%
XOMAO

XOMAP
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Mr. Hughes has served as XOMA’s Executive Chairman and Interim Chief Executive Officer since January 1, 2023. “The rest of the Board and I have been impressed with Owen’s leadership over the past year and his vision to establish XOMA as the p

GlobeNewswire 3 months ago

XOMA
+1.40%
XOMAO

XOMAP
XOMA Announces Stock Repurchase Program of up to $50 Million

Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder returnEMERYVILLE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized XOMA’s first stock repurchase program, which permits the Company to purchase up to $50 million of XOMA’s common stock through January 2027. “Upon

GlobeNewswire 3 months ago

XOMA
+1.40%
XOMAO

XOMAP
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s capabilities as a leading provider of capital to emerging biotech companies EMERYVILLE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced it entered into a non-dilutive, non-recour

GlobeNewswire 3 months ago

XOMA
+1.40%
XOMAO

XOMAP
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of multiple Phase 3 programs by year-end EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent

GlobeNewswire 5 months ago

XOMA
+1.40%
XOMAO

XOMAP
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has grant

GlobeNewswire 5 months ago

XOMA
+1.40%
XOMAO

XOMAP
Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 32% gain

The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...

Simply Wall St. 5 months ago

XOMA
+1.40%
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 9:30 AM ET. The conference is being held in New York, NY. The presentation can be accessed at https://bit.ly/3qJMUgT or by visiting the investor relations section of the company’s website at www.xoma.co

GlobeNewswire 7 months ago

XOMA
+1.40%
XOMAO

XOMAP
10 Stocks That Are About To Explode

In this piece, we will take a look at ten stocks that are about to explode. If you want to skip our background of the stock market then take a look at 5 Stocks That Are About To Explode. The stock market has been quite tumultuous recently. The Federal Reserve’s rapid interest rate hikes that […]

Insider Monkey 7 months ago

DISH

JYNT

ATLO
Owning 35% shares,institutional owners seem interested in XOMA Corporation (NASDAQ:XOMA),

Key Insights Significantly high institutional ownership implies XOMA's stock price is sensitive to their trading...

Simply Wall St. 8 months ago

XOMA
+1.40%
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug Application in third quarter of 2023 EMERYVILLE, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2023 financial results and highlighted recent

GlobeNewswire 8 months ago

XOMA
+1.40%
XOMAO

XOMAP

Performance Overview

Return	XOMA	S&P 500
YTD	+32.92%	+5.06%
1-Year	+26.56%	+20.71%
3-Year	-34.43%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

XOMA Corporation (XOMA)

XOMA Corporation Announces Closing of Tender Offer

XOMA Declares Quarterly Preferred Stock Dividends

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

XOMA to Present at Upcoming Investor Conferences in March

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Announces Stock Repurchase Program of up to $50 Million

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 32% gain

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

10 Stocks That Are About To Explode

Owning 35% shares,institutional owners seem interested in XOMA Corporation (NASDAQ:XOMA),

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

Performance Overview